Atacand HCT Related Published Studies
Well-designed clinical trials related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. [2009]
Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care. [2009]
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. [2008.12]
[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals] [2005]
Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. [2004.12]
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. [2003.09]
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. [2002.11]
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. [2001.05]
Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. [2001]
Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial. [2000.11]
Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. [2000.11]
Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. [2000.09]
Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. [2000.05]
Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. [2000.04]
Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide. [2000]
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. [1999.11.18]
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. [1999.08.01]
Pharmacokinetic drug interaction studies with candesartan cilexetil. [1997.09]
Well-designed clinical trials possibly related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
Study on COgnition and Prognosis in the Elderly (SCOPE). [1999]
Other research related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide. [2011.12]
Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. [2011.08]
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). [2011]
Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel
group, efficacy, and tolerability study of high-dose candesartan cilexetil
combined with hydrochlorothiazide in Korean adults with stage II hypertension. [2011]
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. [2010]
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. [2009]
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ] [2008.01.17]
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. [2008]
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. [2007.09]
[Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension] [2007.01.19]
Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. [2006]
Candesartan cilexetil in cardiovascular disease. [2004.11]
Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. [2004.05]
Candesartan cilexetil: an update of its use in essential hypertension. [2002]
Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. [2002]
Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. [2001.12]
Candesartan cilexetil: an angiotensin II-receptor blocker. [2000.04.15]
Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. [1999.01]
Candesartan cilexetil. A review of its use in essential hypertension. [1998.11]
Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. [1997.12]
Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. [1997.09]
Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. [1997.09]
Other possibly related research studies
Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers. [2005.05]
A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. [2005]
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. [2005]
Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. [2004.04]
The sartans are coming! [2000.03]
Combination therapy with AT(1)-receptor blockers. [2002.08]
Gateways to clinical trials. [2002.05]
AT1-receptor blocker-based combination therapy in hypertension. [2001]
Lercanidipine: a review of its use in hypertension. [2000.11]
Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade. [2000]
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. [2000.04]
Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. [1997.05]
[The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist, for essential hypertension] [1999.05]
Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. [2007]
Olmesartan medoxomil: a review of its use in the management of hypertension. [2008]
|
